This buyback authorization permits the pharmacy operator to repurchase shares of its stock through open market purchases. Fairview Capital Investment Management LLC's holdings in Walgreens Boots Alliance were worth $207,000 at the end of the most recent quarter.
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The NASDAQ listed company saw a recent bid of $23.45 and 4383534 shares have traded hands in the session. Schwab Charles Investment Management Inc. now owns 3,019,739 shares of the pharmacy operator's stock valued at $236,476,000 after purchasing an additional 154,995 shares in the last quarter.
Analyst Thoughts About Walgreens Boots Alliance, Inc. Pathstone Family Office LLC now owns 1,179 shares of the pharmacy operator's stock valued at $1,969,000 after purchasing an additional 818 shares during the last quarter. Institutional investors and hedge funds own 59.98% of the company's stock. (NASDAQ:WBA) plunged -5.18% with the closing price of $71.60.
On 7/25/2017 William C Foote, Director, sold 2,736 with an average share price of $79.79 per share and the total transaction amounting to $218,305.44. The company has a current ratio of 0.96, a quick ratio of 0.47 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $74,780.00, a P/E ratio of 19.98, a price-to-earnings-growth ratio of 1.30 and a beta of 1.22. Over the 52-week time span, the stock notched a high price of $88 and its minimum price was $63.82. (NASDAQ:WBA) tumbled -1.4% year-to-date. The pharmacy operator reported $1.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.04.
According to the company, for the first quarter, net sales increased 7.9% to $30.74 billion, which beat analysts' estimates of $30.35 billion. Walgreens Boots Alliance had a net margin of 3.52% and a return on equity of 16.76%. On average, equities research analysts predict that Walgreens Boots Alliance, Inc. will post $5.00 EPS for the current year.
Walgreens Boots Alliance, the holding company that owns Walgreens, Boots, and a number of pharmaceutical companies, announced that in 2017, it decreased its total carbon footprint by 6.5% from the previous year through energy efficiency programs and projects.
Not only is it important to look at the fundamentals, you want to see how many people inside the company own the stock, meaning their values are aligned with what the investors are expecting.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Wednesday, February 15th will be given a dividend of $0.375 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.12%. The ex-dividend date of this dividend is Monday, February 13th. Walgreens Boots Alliance's dividend payout ratio is now 44.20%.
In other news, Director John Anthony Lederer purchased 20,000 shares of the stock in a transaction that occurred on Thursday, October 26th. The company has its outstanding shares of 994.72M. The disclosure for this sale can be found here.
A number of research firms have recently issued reports on WBA. Pivotal Research set a $73.00 target price on shares of Walgreens Boots Alliance and gave the company a "hold" rating in a research report on Friday. Morgan Stanley cut shares of Walgreens Boots Alliance from an "overweight" rating to an "equal weight" rating and reduced their price objective for the company from $95.00 to $85.00 in a research note on Friday, October 6th. Vetr raised shares of Walgreens Boots Alliance from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, December 12th.
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now. and Walgreens Boots Alliance wasn't one of them!
Analysts have given a mean recommendation of 2.20 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Guardian Life Insurance Co. of America grew its stake in Walgreens Boots Alliance by 0.7% in the first quarter.
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and worldwide trademark & copyright laws.
WBA has been the subject of several research reports.
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the United States.